BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

In Phase A, individuals will receive various doses and schedules of oral ABBV-744 pill to establish Risk-free dosing regimen. Supplemental members is going to be enrolled on the identified monotherapy dosign routine. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 are going to be specified as "insert-on" therapy. In Segment C,